US equities |
SPCX $168.93 ▲+6.27% NVDA $237.76 ▲+1.63% MU $1,063.71 ▼-1.04% TSLA $379.57 ▲+2.42% MSFT $525.32 ▲+1.50% SNDK $1,714.95 ▼-0.29% INTC $117.10 ▼-1.87% META $743.90 ▲+2.17%
FinancialContent

Articles published by Catalyst Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
News headline image
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
< Previous 1 2 3 Next >